Engineered T cells can fight malignant T cells
- PMID: 26294714
- DOI: 10.1182/blood-2015-07-652057
Engineered T cells can fight malignant T cells
Abstract
In this issue of Blood, Mamonkin and colleagues report genetically engineered T cells with specificity for the lineage marker CD5 selectively kill T-lymphoma but not normal T cells, although both express the CD5 target antigen.
Comment on
- 
  
  A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.Blood. 2015 Aug 20;126(8):983-92. doi: 10.1182/blood-2015-02-629527. Epub 2015 Jun 8. Blood. 2015. PMID: 26056165 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
 
        
